Spark Therapeutics, Inc. (NASDAQ:ONCE) insider Daniel Faga sold 7,500 shares of the company’s stock in a transaction dated Tuesday, October 24th. The shares were sold at an average price of $80.96, for a total value of $607,200.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Daniel Faga also recently made the following trade(s):

  • On Tuesday, September 19th, Daniel Faga sold 1,500 shares of Spark Therapeutics stock. The shares were sold at an average price of $85.00, for a total value of $127,500.00.
  • On Tuesday, September 12th, Daniel Faga sold 6,000 shares of Spark Therapeutics stock. The stock was sold at an average price of $82.50, for a total value of $495,000.00.
  • On Thursday, September 7th, Daniel Faga sold 3,000 shares of Spark Therapeutics stock. The shares were sold at an average price of $85.02, for a total value of $255,060.00.

Spark Therapeutics, Inc. (NASDAQ:ONCE) traded up 2.15% during mid-day trading on Tuesday, reaching $85.49. The company had a trading volume of 728,329 shares. The stock has a 50 day moving average of $85.26 and a 200 day moving average of $85.26. Spark Therapeutics, Inc. has a 52 week low of $35.07 and a 52 week high of $91.75. The stock’s market capitalization is $2.67 billion.

Spark Therapeutics (NASDAQ:ONCE) last posted its earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.89) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.75) by ($0.14). Spark Therapeutics had a negative net margin of 962.72% and a negative return on equity of 59.74%. The business had revenue of $1.48 million during the quarter, compared to analysts’ expectations of $1.33 million. During the same quarter in the prior year, the firm earned ($1.04) EPS. Spark Therapeutics’s revenue for the quarter was up 14.7% compared to the same quarter last year. Analysts anticipate that Spark Therapeutics, Inc. will post ($7.59) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Daniel Faga Sells 7,500 Shares of Spark Therapeutics, Inc. (ONCE) Stock” was first posted by American Banking News and is the property of of American Banking News. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/10/24/daniel-faga-sells-7500-shares-of-spark-therapeutics-inc-once-stock.html.

Several brokerages have recently issued reports on ONCE. Cantor Fitzgerald reiterated a “buy” rating on shares of Spark Therapeutics in a research report on Friday, August 25th. William Blair began coverage on shares of Spark Therapeutics in a research report on Wednesday, June 28th. They set an “outperform” rating on the stock. Raymond James Financial, Inc. assumed coverage on shares of Spark Therapeutics in a research report on Thursday, October 12th. They set an “outperform” rating and a $96.00 price objective on the stock. Chardan Capital upgraded shares of Spark Therapeutics from a “neutral” rating to a “buy” rating and boosted their price target for the company from $60.00 to $100.00 in a report on Tuesday, August 8th. Finally, BidaskClub upgraded shares of Spark Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, August 26th. Two analysts have rated the stock with a sell rating, two have given a hold rating and eighteen have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $90.47.

A number of large investors have recently bought and sold shares of ONCE. Ameritas Investment Partners Inc. raised its position in Spark Therapeutics by 23.6% in the second quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock valued at $122,000 after purchasing an additional 389 shares during the period. Cubist Systematic Strategies LLC purchased a new stake in shares of Spark Therapeutics in the 2nd quarter valued at $143,000. BNP Paribas Arbitrage SA raised its holdings in shares of Spark Therapeutics by 530.1% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 2,911 shares of the biotechnology company’s stock valued at $174,000 after buying an additional 2,449 shares during the period. Pacad Investment Ltd. raised its holdings in shares of Spark Therapeutics by 75.0% in the 2nd quarter. Pacad Investment Ltd. now owns 3,500 shares of the biotechnology company’s stock valued at $209,000 after buying an additional 1,500 shares during the period. Finally, Highbridge Capital Management LLC purchased a new stake in shares of Spark Therapeutics in the 1st quarter valued at $227,000. Institutional investors own 77.29% of the company’s stock.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Insider Buying and Selling by Quarter for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.